Triple negative breast cancerImmunogenic cell deathImmunoadjuvantα5β1-targeted micellar paclitaxel (ATN-MPTX) shows high selectivity and strong ICD in murine 4T1 cells.ATN-MPTX diaplays superior inhibition of
Cancer immunotherapy has revolutionized the field of cancer therapy. However, immunotherapy alone has moderate efficacy in many advanced cancers such as triple-negative breast cancer (TNBC)1,2,3,4. TNBC is considered the subtype that can benefit the most from immunotherapy among breast cancer5,6bec...
Molecular Cancer (2024) 23:230 https://doi.org/10.1186/s12943-024-02150-4 Molecular Cancer RESEARCH Open Access Tumor‑intrinsic role of ICAM‑1 in driving metastatic progression of triple‑negative breast cancer through direct interaction with EGFR Jae‑Hyeok Kang1†, Nizam...
Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer because of its young onset, high risk of early recurrence and metastasis. Due to the special molecular biological characteristics, there is still no clear therapeutic target for TNBC, and chemotherapy is still the...
Triple-negative breast cancer accounts for 15% of all breast cancer cases, and it has a lower survival rate and higher incidence of early recurrence, parti
The combination of programmed cell death ligand-1 (PD-L1) immune checkpoint blockade (ICB) and immunogenic cell death (ICD)-inducing chemotherapy has shown promise in cancer immunotherapy. However, triple-negative breast cancer (TNBC) patients undergoing
Triple-negative breast cancer (TNBC) is recognized as a particularly aggressive subtype of breast cancer that is devoid of effective therapeutic targets. Immune checkpoint inhibitors (ICIs) have demonstrated promising results in TNBC treatment. Nonethele
Immunotherapy has recently emerged as a treatment strategy which stimulates the human immune system to kill tumor cells. Tumor immunotherapy is based on immune editing, which enhances the antigenicity of tumor cells and increases the tumoricidal effect o
Both LINK-A expression and LINK-A-dependent signalling pathway activation correlate with triple-negative breast cancer (TNBC), promoting breast cancer glycolysis reprogramming and tumorigenesis. Our findings illustrate the magnitude and diversity of cytoplasmic lncRNAs in signal transduction and highlight ...
Triple negative breast cancer (TNBC) does not respond to checkpoint blockade immunotherapy as a result of immunosuppressive tumor microenvironment. To remodel the tumor microenvironment, we developed a liposome formulation to deliver a potential immunogenic cell death (ICD) inducing agent, 17-(allylamino...